Familial hypercholesterolaemia 24 items
Trials, agents, guidance
- Trial BROOKLYN
Studies
- BROOKLYN: obicetrapib cuts LDL-C by 36.3% and Lp(a) by 45.9% in 354 patients with heterozygous familial hypercholesterolaemia (Nat Med 2026)
- BROADWAY: obicetrapib lowers LDL-C by 29.9% versus 2.7% with placebo in 2,530 high-risk patients (N Engl J Med 2025)
- REALIZE phase 3 trial: anacetrapib cuts LDL-C by 39·7% versus placebo in familial hypercholesterolaemia over one year (Lancet 2015)
- CETP Taq1B B2B2 genotype predicts higher cardiovascular risk despite equal statin response in familial hypercholesterolemia (Eur J Hum Genet 2005)
- High baseline CETP predicts worse atherosclerosis progression on statins in familial hypercholesterolemia (Atherosclerosis 2004)
- Obicetrapib lowers Lp(a) by 37% in a 2,356-patient pooled analysis, with similar absolute reduction across baseline strata (Eur Heart J 2026)
- Pooled phase 3 safety data on 2,880 patients show obicetrapib matches placebo for adverse events, with no blood pressure signal (Am J Prev Cardiol 2026)
- CETP haplotype independently predicts triglyceride response to fluvastatin in familial hypercholesterolemia (Atherosclerosis 2005)
- CETP TaqIB B2 allele produces a less atherogenic lipid profile and fewer clinical signs in familial hypercholesterolemia (Metabolism 2001)
- Rationale and design of BROADWAY and BROOKLYN: 2,886 participants randomised to test obicetrapib on top of maximally tolerated therapy (Am Heart J 2024)
- Modeling shows adding a CETP inhibitor would push LDL-target attainment above 95 percent in familial hypercholesterolemia, versus just 54 percent with ezetimibe alone (J Clin Lipidol 2018)
- In Japanese patients with familial hypercholesterolaemia, anacetrapib cuts LDL-C by nearly 30% versus placebo in 12 weeks (Atherosclerosis 2016)
- Familial hypercholesterolemia patients show elevated CETP-mediated cholesteryl ester transfer and defective reverse cholesterol transport (Arterioscler Thromb Vasc Biol 2011)
- Elevated CETP mass helps explain smaller, denser LDL particles in familial hypercholesterolemia (J Lipid Res 2004)
- Higher CETP concentration is linked to coronary plaques in familial hypercholesterolemia, but not independently after adjustment (J Clin Lipidol 2026)
- CETP mutations are identified for the first time in South Indian patients with familial hypercholesterolemia (Clin Chim Acta 2022)
- CETP TaqIB B2 allele blunts the post-meal fat spike in patients with familial hypercholesterolemia (Clin Chem Lab Med 2007)
- Probucol raises CETP and LCAT activity despite lowering HDL, reframing its HDL reduction as pro-transport rather than atherogenic (Atherosclerosis 2000)
- Splice-site CETP mutations are found in 10% of a South Indian familial hypercholesterolemia cohort (Cureus 2025)
- Whole-genome sequencing of unexplained severe familial hypercholesterolaemia turns up a novel CETP deletion variant (Vavilovskii Zhurnal Genet Selektsii 2023)
- Review ranks CETP and ANGPTL3 inhibition among the most promising novel LDL-lowering strategies (Curr Opin Lipidol 2018)
- A young man with familial hypercholesterolaemia is found to also carry heterozygous CETP deficiency (Intern Med 1998)
Video and podcasts